Verve Therapeutics Nosedives after Q3 Loss; FDA Hold on VERVE-101
Market News

Verve Therapeutics Nosedives after Q3 Loss; FDA Hold on VERVE-101

Shares of gene editing technology company Verve Therapeutics (NASDAQ:VERV) are tanking today after reporting a wider-than-expected third-quarter loss.

The top line came in at $0.93 million, ahead of expectations by $0.1 million. Net loss per share at $0.79 though came in wider than estimates by $0.06. The company had a cash pile of $550.7 million at the end of September.

Separately, the U.S. Food and Drug Administration placed a hold on Verve’s IND application for its product candidate VERVE-101.

The company had requested clearance to conduct a clinical trial of the drug for the treatment of heterozygous familial hypercholesterolemia.

Shares of the company are down nearly 20% today as a result.

Read full Disclosure

Go Ad-Free with Our App